A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropat ...